XIAP and cancer: Considerable evidence has now accrued through application of a broad range of technologies to a wide spectrum of in vitro and in vivo model systems to substantiate XIAP as a valid molecular target in cancer therapeutics (Lacasse et al, 2005; Wright and Duckett, 2005; Schimmer et al, 2006).